Вот умеют американцы делать бизнес на всем.
Сначала раскормили нацию ,потом сажают на лекарства для борьбы с лишним весом .
The use of all the GLP-1s or co-agonist medications “led to decreased body mass index (BMI), waist circumference, SBP (systolic blood pressure), and DBP (diastolic blood pressure),” wrote the authors in the Annals of Internal Medicine. All the medications had a similar safety profile.
Худеют благодаря нарушению процессов переварения и вызывания рвоты и тошноты при виде пищи 🤑
The most common adverse events for all GLP-1s were gastrointestinal (GI), such as nausea, diarrhea, constipation, and vomiting. Across all agents, 60%-80% of patients taking the medications experienced a GI adverse event, although most were transient, according to the authors. A total of 6%-26% of patients discontinued treatment as a result of a side effect.
И зарабатывают ещё больше денег .
Analysts have forecast the market for GLP-1 drugs could reach at least $150 billion a year by the early 2030s.
[Login to see the link]